Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acrivon Therapeutics, Inc.’s SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on precision oncology. Its 8-K reports cover results of operations, financial condition, Regulation FD presentations, pipeline updates for ACR-368 and ACR-2316, and disclosures related to its internal CLIA-certified laboratory and companion diagnostic activities.
The company’s proxy materials describe annual meeting matters, board elections, auditor ratification, executive and director governance, and stockholder voting procedures. Filing records also identify the company’s common stock registration on Nasdaq and provide exhibits that support business updates, clinical program presentations, material agreements, and risk-related public-company reporting.
Acrivon Therapeutics insider transaction summary: Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, reported a single Form 4 transaction. On 08/14/2025 the reporting person had 613 shares withheld at a price of $1.39 per share as a result of tax withholding tied to the vesting of restricted stock units. After this withholding disposition, the reporting person beneficially owns 65,921 shares of Acrivon common stock, held directly. The Form 4 was signed by an attorney-in-fact on 08/18/2025. The filing notes the withholding was to satisfy mandatory tax obligations and includes a Power of Attorney exhibit.
Acrivon Therapeutics insiders reported routine post-vesting share dispositions on 08/14/2025. The Form 4 shows that restricted stock units were treated by the issuer to cover mandatory tax withholding: 59,766 shares were withheld at an effective price of $1.39, recorded as a disposition. After that transaction, Peter Blume-Jensen is shown as beneficially owning 2,146,345 shares (direct) and 315,196 shares (indirect) attributable to spouse holdings. A separate small disposition of 490 shares at $1.39 is reported as indirect ownership. Both Dr. Blume-Jensen (President and CEO) and Dr. Kristina Masson (EVP, Business Operations) are listed as reporting persons and each signed via attorney-in-fact on 08/18/2025.
Acrivon Therapeutics (ACRV) presented interim financials and clinical progress through June 30, 2025. The company recorded a six-month net loss of $40.7 million, bringing an accumulated deficit to $237.7 million, and reported cash, cash equivalents and investments of $147.6 million, which management says funds operations into the second quarter of 2027. Acrivon remains pre-revenue and continues to invest heavily in R&D.
Clinically, ACR-368 is in a registrational-intent Phase 2 program for endometrial cancer using the proprietary OncoSignature biomarker; an interim cohort of OncoSignature-positive patients showed a 35% confirmed overall response rate and tumor shrinkage in 80% of patients. ACR-2316 is in Phase 1 with early target engagement and a confirmed partial response observed at Dose Level 3. The company retains licensed rights to prexasertib under a Lilly agreement with up to $168 million in milestone payments and tiered royalties up to 10%.
This Schedule 13G/A reports that Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC and Frank M. Sands jointly beneficially own 2,122,605 shares of Acrivon Therapeutics common stock, representing 6.8% of the outstanding shares based on 31,355,361 shares reported by the issuer. The filing shows no sole voting or dispositive power and indicates shared voting and dispositive power over the reported shares, consistent with a passive investor position.
The filing names the reporting entities, identifies their places of organization (Cayman Islands, Delaware and United States), provides the issuer's principal office address, and includes a certification that the securities were not acquired to change or influence control of the issuer.